Investigational drug · Phase 3
HRS9531
Not approved by FDA. In 13 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
13
9 still active
All registered trials
33
Any phase or sponsor naming "HRS9531"
First trial start
2024
May 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS9531", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Chronic Management of Body Weight
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Heart Failure With Preserved Ejection Fraction
- Atherosclerotic Cardiovascular Disease
- Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy
- Bstructive Sleep Apnea (OSA) and Obesity
- T2DM
- Obesity
- Diabetes Mellitus, Type 2
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Heart failure · MASH (fatty liver disease) · Cardiovascular and metabolic · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS9531" as an intervention, largest first.
- A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular DiseasePivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07551492 · 9,262 participants (planned) · Start May 29, 2026 · Primary completion May 24, 2031
Drug: HRS9531; HRS9531 placebo · For: Atherosclerotic Cardiovascular Disease
Sites: Beijing, China
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 DiabetesPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06649344 · 884 participants · Start Oct 31, 2024 · Primary completion Jul 18, 2026
Drug: HRS9531 Injection; Semaglutide Injection · For: Type 2 Diabetes
Sites: Tianjin, China
- A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese SubjectsPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07670884 · 675 participants (planned) · Start Jul 24, 2026 · Primary completion Oct 31, 2027
Drug: HRS9531 Tablet; HRS9531 Tablet Placebo · For: Chronic Management of Body Weight
Sites: Zhengzhou, China; Nanjing, China
- A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With ObesityPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07285902 · 572 participants · Start Dec 25, 2025 · Primary completion Mar 2027
Drug: HRS9531 injection; Semaglutide Injection · For: Obesity
Sites: Beijing, China; Nanjing, China
- To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or ObesePivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06396429 · 567 participants · Start May 13, 2024 · Primary completion Jul 7, 2025
Drug: HRS9531 injection; HRS9531 injection and 2 more · For: Overweight or Obesity
Sites: Shanghai, China
- Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal InsulinPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07060456 · 300 participants (planned) · Start Jul 25, 2025 · Primary completion Feb 2027
Drug: HRS9531; HRS9531 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without DiabetesPivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT05881837 · 249 participants · Start Jun 13, 2023 · Primary completion Oct 13, 2024
Drug: HRS9531 injection; HRS9531 injection and 6 more · For: Overweight or Obesity
Sites: Hefei, China; Beijing, China; Chongqing, China · 25 sites in all
- A Research Study to Investigate the Efficacy and Safety of HRS9531 Tablets in Participants With Type 2 Diabetes MellitusPivotal-lookingRecruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07599410 · 240 participants (planned) · Start Jul 14, 2026 · Primary completion May 2027
Drug: HRS9531 Tablet; HRS9531 Tablet and 4 more · For: T2DM
Sites: Beijing, China; Jinan, China
- the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise AlonePivotal-lookingCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06650007 · 218 participants · Start Nov 8, 2024 · Primary completion Jan 21, 2026
Drug: HRS9531 Injection; HRS9531 Placebo Injection · For: Diabetes Mellitus, Type 2
Sites: Changsha, China
- HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection FractionPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06391710 · 203 participants · Start May 6, 2024 · Primary completion Jan 2026
Drug: HRS9531; Placebo · For: Heart Failure With Preserved Ejection Fraction
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist.
He K, Wei Y, Zhao H, et al. · Diabetes Obes Metab 2026
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
- HDM1005Phase 35 trials
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Obstructive Sleep Apnea (OSA) and Obesity, Obesity, Type 2 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.